查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1738576

全球吸入抗生素市场规模（按产品类型、应用、分销管道、区域范围和预测）

Global Inhaled Antibiotics Market Size By Product Type (Aerosol/Metered Dose Inhaler, Dry Powder Formulation), By Application (Pneumonia, Asthma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

吸入抗生素的市场规模和预测

2024 年吸入式抗生素市场规模为 12.8 亿美元，预计到 2032 年将达到 20.6 亿美元，预测期内（2026-2032 年）的复合年增长率为 6.17%。

近年来，由于气喘、慢性阻塞性肺病(COPD)、支气管炎和新冠肺炎 (COVID-19) 等慢性呼吸系统疾病的发生率不断上升，全球吸入式抗生素市场发展势头强劲。此外，不断增加的研发投入和企业动机是吸入式抗生素的成长要素，预示着预测期内吸入式抗生素市场将拥有巨大的成长机会。全球吸入式抗生素市场报告对市场进行了全面评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义全球吸入抗生素市场

吸入式抗生素包括妥布霉素和粘菌素的雾化和干粉剂，以及雾化Aztreonam。吸入式抗生素主要用于治疗呼吸道感染疾病。引起支气管扩张的慢性呼吸道疾病伴随难以治疗的感染疾病，是治疗上的一大挑战。患有囊性囊肿纤维化(CF) 和非 CF 支气管扩张等慢性呼吸道疾病的患者容易受到铜绿假单胞菌、抗药性金黄色葡萄球菌、鼠伤寒伯克霍尔德菌和非结核分枝桿菌的混合感染疾病的折磨。

吸入式抗生素的优点在于，它能够将高浓度的药物输送至感染疾病部位，而不会产生肠外或口服抗生素治疗常见的全身性副作用。近几十年来，人们对开发吸入式抗生素以帮助控制感染疾病（尤其是感染疾病难以根除或復发率高的感染）的兴趣日益浓厚。与全身性疗法相比，吸入式抗生素在治疗下呼吸道感染疾病方面具有显着优势。

全球吸入抗生素市场概况

慢性呼吸道感染疾病可透过吸入式抗生素治疗。这些吸入式抗生素被认为比其他途径更有效，因为它们能在标靶输送更高的药物浓度，这很可能促进吸入式抗生素市场的成长。气喘、肺炎、慢性阻塞性肺病(COPD) 和支气管炎等呼吸系统疾病的盛行率不断上升，预计将推动整个吸入式抗生素市场的成长。气喘也是影响全球数百万人的主要公共卫生问题。

慢性阻塞性肺病(COPD) 是另一种危及生命的肺部疾病，会导致过早死亡和高死亡率。慢性支气管炎和肺气肿都是慢性阻塞性肺病的症状。此外，新产品研发活动的活性化也有望推动吸入式抗生素市场的成长。吸入式抗生素长期以来一直用于治疗囊肿纤维化患者的肺部感染疾病，并且也正在研究其用于治疗其他肺部感染疾病途径，尤其是针对多重抗药性和广泛抗药性的患者，例如结核病。

另一方面，吸入药物的副作用以及难以开发出一种能够治疗多种疾病的有效吸入装置，可能会阻碍吸入抗生素市场的成长。此外，由于运输设施不规范，抗生素生产所需的原料药（API）等原料供应不足，预计将影响吸入抗生素市场的全球分销管道。

目录

第 1 章全球吸入抗生素市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

4. 全球吸入抗生素市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球吸入抗生素市场（依产品类型）

  • 概述
  • 气雾剂/定量吸入器
  • 干粉配方
  • 喷
  • 其他的

6. 全球吸入抗生素市场（依应用）

  • 概述
  • 肺炎
  • 气喘
  • 支气管炎
  • 其他的

7. 全球吸入抗生素市场（依通路）

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局

8. 全球吸入式抗生素市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

9. 全球吸入抗生素市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Gilead Sciences
  • Aradigm
  • Lupin Ltd.
  • Polyphor
  • Insmed Incorporated
  • Pharmaero
  • Savara Pharmaceuticals
  • Joincare Pharmaceutical Group
  • Pharmaxis Ltd.
  • Raptor Pharmaceutical Corp.
  • Teva Canada Limited.
  • Altan Pharmaceuticals.

第十一章 附录

  • 相关调查
简介目录
Product Code: 62047

Inhaled Antibiotics Market Size And Forecast

Inhaled Antibiotics Market size was valued at USD 1.28 Billion in 2024 and is projected to reach USD 2.06 Billion by 2032, growing at a CAGR of 6.17% during the forecasted period 2026 to 2032.

Global Inhaled Antibiotics Market has gained momentum in recent times because of the increasing incidence of chronic respiratory disorders such as asthma, chronic obstructive pulmonary diseases (COPD), bronchitis, and COVID-19. Furthermore, an increase in research and development and company initiatives are the factors for the growth of the inhaled antibiotics which shows significant opportunities for Inhaled Antibiotics Market growth over the forecast period. The Global Inhaled Antibiotics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Inhaled Antibiotics Market Definition

Inhaled antibiotics include nebulized and dry powder versions of tobramycin and colistin, as well as nebulized aztreonam. Inhaled antibiotics are primarily used to treat infections of the respiratory tract. Chronic respiratory disorders that cause bronchiectasis are associated with difficult-to-treat infections, posing a significant therapeutic challenge. Complex infections caused by Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species, and non-tuberculous Mycobacteria can afflict patients with chronic respiratory disorders such as cystic fibrosis (CF) and non-CF bronchiectasis.

The benefits of inhaled antibiotics include the ability to deliver large concentrations of medication at the site of infection without the systemic adverse effects seen with parenteral or oral antibiotic treatments. Over the last few decades, there has been a surge in interest in the creation of inhaled antibiotics to aid in the management of infections, particularly those that are difficult to eradicate or have a high recurrence rate. When compared to systemic therapy, antibiotic delivery by inhalation has significant advantages for treating lower airway infections.

Global Inhaled Antibiotics Market Overview

Chronic respiratory airway infections are treated with inhalation antibiotics. These inhaled antibiotics are thought to be more effective than other routes since they provide a higher concentration of medications to the targeted site, which may contribute to the growth of the Inhaled Antibiotics Market. Rising incidence of respiratory diseases such as asthma, pneumonia, chronic obstructive pulmonary diseases (COPD), and bronchitis is expected to drive the growth of the overall Inhaled Antibiotics Market. Asthma is also a major public health issue that affects millions of people worldwide.

Chronic obstructive pulmonary disease (COPD) is another life-threatening lung illness that causes premature death and high mortality rates. Chronic bronchitis and emphysema are both symptoms of Chronic Obstructive Pulmonary Disease (COPD). Moreover, the increasing research and development activities for the development of novel products are also anticipated to boost the Inhaled Antibiotics Market growth. Inhaled antibiotics have long been used to treat pulmonary infections in cystic fibrosis patients, and the pulmonary route is also being explored for other infectious disorders such as tuberculosis especially, with multidrug-resistant and extensively drug-resistant patients.

Whereas side effects associated with drug inhalation and the difficulty of a single effective inhaler device that can treat many disease conditions may hamper the growth of the Inhaled Antibiotics Market. Additionally, the insufficient supply of raw materials such as APIs for antibiotics manufacturing because of irregularities in the transportation facility will affect the global distribution channel of the Inhaled Antibiotics Market.

Global Inhaled Antibiotics Market Segmentation Analysis

The Global Inhaled Antibiotics Market is Segmented into Product Type, Application, Distribution Channel, And Geography.

Inhaled Antibiotics Market, By Product Type

  • Aerosol/Metered Dose Inhaler
  • Dry Powder Formulation
  • Spray
  • Others

Based on Product Type, the market is bifurcated into Aerosol/Metered Dose Inhaler, Dry Powder Formulation, Spray, and others. The Metered Dose Inhaler segment accounted for the largest share and is anticipated to maintain its lead over the forecast period. This is attributed to its common use in the asthma and chronic obstructive pulmonary disease (COPD) drug delivery devices market.

Inhaled Antibiotics Market, By Application

  • Pneumonia
  • Asthma
  • Bronchitis
  • Others

Based on Application, the market is bifurcated into Pneumonia, Asthma, Bronchitis, and Others. The asthma segment accounts for the largest share because of genetics or environmental factors such as microbial exposure, passive smoking, and air pollution, the illness burden is increasing in both adults and children, boosting the demand for asthma treatment, which is expected to contribute to the segment's growth.

Inhaled Antibiotics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on Distribution Channel, the market is bifurcated into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The largest market segment is held by retail pharmacies owing to an increase in the popularity of online pharmacies for obtaining prescription pharmaceuticals and customers' consistent use of this distribution channel and due to an increase in the number of treatments administered through them and an increase in the number of retail pharmacies in emerging countries.

Inhaled Antibiotics Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the Global Inhaled Antibiotics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounts for the largest growing segment due to an increase in the incidence of targeted diseases, an increase in the number of FDA approvals, and several product launches in the United States. Furthermore, the region's market is being driven by an increase in awareness about disease management, including prevention, diagnosis, and treatment, and an increased emphasis on respiratory illness care to improve the market in the region.

Key Players

The "Global Inhaled Antibiotics Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Pharmaxis Ltd., Raptor Pharmaceutical Corp., Teva Canada Limited, Altan Pharmaceuticals.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL INHALED ANTIBIOTICS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL INHALED ANTIBIOTICS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL INHALED ANTIBIOTICS MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 Aerosol/Metered Dose Inhaler
  • 5.3 Dry Powder Formulation
  • 5.4 Spray
  • 5.5 Others

6 GLOBAL INHALED ANTIBIOTICS MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Pneumonia
  • 6.3 Asthma
  • 6.4 Bronchitis
  • 6.5 Others

7 GLOBAL INHALED ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1 Overview
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 GLOBAL INHALED ANTIBIOTICS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East And Africa

9 GLOBAL INHALED ANTIBIOTICS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Gilead Sciences
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Aradigm
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Lupin Ltd.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Polyphor
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Insmed Incorporated
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Pharmaero
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Savara Pharmaceuticals
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Joincare Pharmaceutical Group
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Pharmaxis Ltd.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Raptor Pharmaceutical Corp.
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11Teva Canada Limited.
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Altan Pharmaceuticals.
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments

11 Appendix

  • 11.1 Related Research